Maze Therapeutics: BTIG Issues Buy Recommendation with Approximately 100% Price Potential!

Maze Therapeutics (MAZE) focuses on developing precision medications targeting the genetic causes of diseases. The company’s pipeline is dominated by two main programs, MZE829 and MZE782. MZE829 is an orally administered, small molecule APOL1 inhibitor being developed as a potential treatment for patients with APOL1-mediated kidney disease (AMKD). Patient recruitment for the Phase 2 study HORIZON is progressing, with initial proof-of-concept data expected from this study in the first quarter of 2026. The second key program, MZE782, is currently...